Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at Jefferies Group issued their Q2 2017 earnings estimates for Esperion Therapeutics in a note issued to investors on Monday. Jefferies Group analyst M. Yee forecasts that the biopharmaceutical company will earn ($1.38) per share for the quarter. Jefferies Group has a “Hold” rating and a $55.00 price target on the stock. Jefferies Group also issued estimates for Esperion Therapeutics’ Q3 2017 earnings at ($1.40) EPS, Q4 2017 earnings at ($1.42) EPS, FY2017 earnings at ($6.00) EPS and FY2018 earnings at ($5.60) EPS.

Several other brokerages have also issued reports on ESPR. Stifel Nicolaus restated a “buy” rating and set a $60.00 price target (up from $45.00) on shares of Esperion Therapeutics in a research note on Monday, June 26th. BidaskClub raised Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, June 25th. Deutsche Bank AG began coverage on shares of Esperion Therapeutics in a research report on Friday, June 23rd. They issued a “buy” rating and a $48.00 price objective for the company. Citigroup Inc. restated a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, June 22nd. Finally, ValuEngine upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Eight equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $36.51.

TRADEMARK VIOLATION WARNING: “Esperion Therapeutics, Inc. (ESPR) to Post Q2 2017 Earnings of ($1.38) Per Share, Jefferies Group Forecasts” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/07/13/esperion-therapeutics-inc-espr-to-post-q2-2017-earnings-of-1-38-per-share-jefferies-group-forecasts.html.

Shares of Esperion Therapeutics (ESPR) opened at 46.34 on Thursday. The stock’s market cap is $1.05 billion. The stock has a 50 day moving average of $36.52 and a 200-day moving average of $28.03. Esperion Therapeutics has a 52 week low of $9.40 and a 52 week high of $49.69.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Monday, May 1st. The biopharmaceutical company reported ($1.80) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.44) by $0.36. During the same period in the previous year, the company earned ($0.65) EPS.

Institutional investors have recently modified their holdings of the company. Quantbot Technologies LP bought a new stake in shares of Esperion Therapeutics during the first quarter worth about $158,000. C WorldWide Group Holding A S acquired a new stake in Esperion Therapeutics during the first quarter worth $162,000. Princeton Alpha Management LP purchased a new position in shares of Esperion Therapeutics during the first quarter worth approximately $205,000. Bank of Montreal Can increased its position in shares of Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock worth $233,000 after buying an additional 6,000 shares in the last quarter. Finally, American International Group Inc. increased its position in shares of Esperion Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 8,814 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 584 shares in the last quarter. Institutional investors own 81.45% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.